To hear about similar clinical trials, please enter your email below
Trial Title:
Paraneoplastic Syndrome in Hepatocellular Carcinoma Patients
NCT ID:
NCT05846035
Condition:
Hepatocellular Carcinoma Patients
Conditions: Official terms:
Carcinoma
Carcinoma, Hepatocellular
Paraneoplastic Syndromes
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Cross-Sectional
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
Triphasic C.T abdomen and pelvis
Description:
for cirrhotic patients to ensure hepatocellular carcinoma
Other name:
alpha feto protein
Summary:
Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world with rising
incidence. Globally, there has been substantial variation in prevalence of risk factors
for HCC over years, like control of viral hepatitis in developing countries but growing
epidemic of fatty liver disease in developed world. Changing epidemiology of HCC is
related to trends in these risk factors, Paraneoplastic syndromes (PNS) are defined as
systemic, metabolic, or other distant consequences of malignancy resulting, either
directly or indirectly, from production by the neoplasm of substances that gain access to
the blood stream, thereby exerting their effects on distant organs or tissues There is
four major HCC-associated paraneoplastic syndromes among Cirrhotic
patients,i.e.hypercholesterolemia,hypoglycemia,hypercalcemia,and erythrocytosis .
Criteria for eligibility:
Study pop:
- Cirrhotic Patients with HCC.
- HCC will be diagnosed based on Alpha -feto protein (AFP) and dynamic imaging.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
-
- Cirrhotic Patients with HCC.
- HCC will be diagnosed based on Alpha -feto protein (AFP) and dynamic imaging.
Exclusion Criteria:
-
- Patient known to have primary parathyroid disease, patients with bone
metastasis or excessive use of antacids.
- Patients with secondary polycythemia (as chronic hypoxia) and patients with
polycythemia rubra vera.
- Patients with acute infections or GIT bleeding.
- Patients with preexisting dyslipidemia.
- Patients with significant cholestasis.
Gender:
All
Minimum age:
40 Years
Maximum age:
100 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Sohag University hospitals
Address:
City:
Sohag
Country:
Egypt
Status:
Recruiting
Contact:
Last name:
Magdy M Amin, Professor
Start date:
April 15, 2023
Completion date:
April 30, 2024
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05846035
